Ranbaxy Laboratories has dipped 5.35% to Rs 335, in noon deals on the NSE, after PTI reports suggest that the Supreme Court has issued a notice to the pharmaceutical company and Centre on a PIL (Public Interest Litigation) seeking probe against the company for allegedly supplying adulterated drugs in the country.
The Supreme Court has, however, refused to pass an interim order to restrain Ranbaxy from manufacturing drugs, added report.
Meanwhile, shares of drug maker has fallen nearly 10% in past six trading sessions from Rs 370 on March 7, after the company has recalled some batches of its generic version of cholesterol-lowering Lipitor drug in the US after a dosage mix-up was detected. The benchmark CNX Nifty has declined 1.4% during the same period.
The stock opened at Rs 352 and touched a high of Rs 353 on the NSE. A combined 2.63 million shares changed hands on the counter till 1240 hours on the BSE and NSE.
The Supreme Court has, however, refused to pass an interim order to restrain Ranbaxy from manufacturing drugs, added report.
Meanwhile, shares of drug maker has fallen nearly 10% in past six trading sessions from Rs 370 on March 7, after the company has recalled some batches of its generic version of cholesterol-lowering Lipitor drug in the US after a dosage mix-up was detected. The benchmark CNX Nifty has declined 1.4% during the same period.
The stock opened at Rs 352 and touched a high of Rs 353 on the NSE. A combined 2.63 million shares changed hands on the counter till 1240 hours on the BSE and NSE.
